RBMY1E Activators
RBMY1E activators operate through intricate signaling pathways that culminate in the increased functional activity of this RNA-binding protein. One primary mechanism involves the elevation of intracellular cyclic AMP (cAMP), a pivotal second messenger in cellular signaling. The increase in cAMP levels is often the result of activation of adenylate cyclase or inhibition of phosphodiesterases, which are enzymes responsible for the degradation of cAMP. Once elevated, cAMP activates protein kinase A (PKA), a kinase that plays a significant role in phosphorylation events within the cell. The activation of PKA creates a cascade of phosphorylation that can lead to the functional enhancement of RBMY1E, optimally positioning it for its role in RNA processing and metabolic regulation.
The biochemical landscape within a cell is a complex network of interdependent pathways, and the modulation of one can influence others. Certain compounds that serve as beta-adrenergic agonists or that inhibit specific phosphodiesterase enzymes contribute to the rise in cAMP levels. This, in turn, activates PKA, furthering the phosphorylation and potential activity of RBMY1E. Additionally, the presence of flavonoids that inhibit phosphodiesterase activity can also result in increased cAMP and consequent PKA activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Acts as a beta-adrenergic agonist, raising cAMP levels and activating PKA, leading to potential enhancement of RBMY1E activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, prevents cAMP degradation, potentially supporting increased RBMY1E activity via PKA. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Stimulates adrenergic receptors, leading to increased cAMP and PKA activation, which can enhance RBMY1E activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective phosphodiesterase 4 inhibitor, prevents cAMP breakdown, potentially leading to increased RBMY1E activity via PKA activation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits phosphodiesterase 5 (PDE5), increases cAMP levels, may enhance RBMY1E activity through PKA pathway activation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Specific PDE3 inhibitor, increases cAMP levels, potentially leading to activation of PKA and subsequent enhancement of RBMY1E activity. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Inhibits PDE3A, increases cAMP and activates PKA, which could enhance RBMY1E activity. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Activates adenylate cyclase, raising cAMP levels, potentially leading to activated PKA and increased RBMY1E activity. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $27.00 $51.00 $101.00 $153.00 $1925.00 | 40 | |
Flavonoid that inhibits PDE4, resulting in increased cAMP and PKA activation, which may indirectly enhance RBMY1E activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
PDE3 inhibitor that raises cAMP levels, potentially enhancing RBMY1E activity through PKA-dependent signaling pathways. | ||||||